search reports
Categories
Categories

Pulmonary Arterial Hypertension - Pipeline Review, H1 2016

Report Code : gmdhc7707idb
Published Date : 30 March, 2016 | No of Pages: 202

  • Report Description
  • Table of Contents
  • Companies Mentioned
  • Related Reports
Pulmonary Arterial Hypertension - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Pipeline Review, H1 2016’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension
- The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Pulmonary Arterial Hypertension Overview 9
Therapeutics Development 10
Pipeline Products for Pulmonary Arterial Hypertension - Overview 10
Pipeline Products for Pulmonary Arterial Hypertension - Comparative Analysis 11
Pulmonary Arterial Hypertension - Therapeutics under Development by Companies 12
Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes 16
Pulmonary Arterial Hypertension - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Pulmonary Arterial Hypertension - Products under Development by Companies 20
Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes 24
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 25
APT Therapeutics, Inc. 25
Arena Pharmaceuticals, Inc. 26
Asahi Kasei Pharma Corp. 27
Ascendis Pharma A/S 28
Bial - Portela & Ca, S.A. 29
Bristol-Myers Squibb Company 30
Carolus Therapeutics, Inc. 31
Celsion Corporation 32
Complexa, Inc. 33
Corridor Pharmaceuticals Inc. 34
Cytokinetics, Inc. 35
Eli Lilly and Company 36
F. Hoffmann-La Roche Ltd. 37
Gilead Sciences, Inc. 38
Insmed Incorporated 39
INVENT Pharmaceuticals, Inc. 40
Johnson & Johnson 41
Kowa Company, Ltd. 42
Mallinckrodt Plc 43
Mezzion Pharma Co. Ltd. 44
miRagen Therapeutics, Inc. 45
Morphogen-IX Limited 46
Nippon Kayaku Co., Ltd. 47
Nippon Shinyaku Co., Ltd. 48
Novartis AG 49
Peloton Therapeutics, Inc. 50
PharmaIN Corporation 51
PhaseBio Pharmaceuticals, Inc. 52
Pluristem Therapeutics Inc. 53
Proteo, Inc. 54
Pulmokine, Inc. 55
Reata Pharmaceuticals, Inc. 56
Respira Therapeutics, Inc. 57
Selten Pharma, Inc 58
Silence Therapeutics Plc 59
SteadyMed Therapeutics, Inc. 60
Suda Ltd 61
Toray Industries, Inc. 62
Pulmonary Arterial Hypertension - Therapeutics Assessment 63
Assessment by Monotherapy Products 63
Assessment by Target 64
Assessment by Mechanism of Action 68
Assessment by Route of Administration 71
Assessment by Molecule Type 73
Drug Profiles 75
Antibody for Pulmonary Arterial Hypertension - Drug Profile 75
Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile 76
APT-602 - Drug Profile 77
bardoxolone methyl - Drug Profile 78
beraprost sodium ER - Drug Profile 81
beraprost sodium SR - Drug Profile 82
BIA-51058 - Drug Profile 83
BMP-9 - Drug Profile 84
CT-2009 - Drug Profile 85
CXA-10 - Drug Profile 86
Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension - Drug Profile 87
fasudil - Drug Profile 88
imatinib mesylate - Drug Profile 89
INS-1009 - Drug Profile 92
INV-240 - Drug Profile 93
JNJ-26993135 - Drug Profile 94
lisuride - Drug Profile 95
MFC-001 - Drug Profile 97
MFC-002 - Drug Profile 98
nitric oxide - Drug Profile 99
Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile 102
Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile 103
PB-1046 - Drug Profile 104
PB-1120 - Drug Profile 106
pitavastatin NP - Drug Profile 107
PK-10453 - Drug Profile 108
PK-10571 - Drug Profile 109
PLX-PAD - Drug Profile 110
PT-2977 - Drug Profile 114
QCC-374 - Drug Profile 115
R-190 - Drug Profile 116
ralinepag - Drug Profile 118
RT-234 - Drug Profile 120
selexipag - Drug Profile 121
selonsertib - Drug Profile 123
sirolimus albumin-bound - Drug Profile 124
Small Molecule for Pulmonary Arterial Hypertension - Drug Profile 126
Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction - Drug Profile 127
Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension - Drug Profile 128
Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile 129
Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile 130
Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile 131
SPI-054 - Drug Profile 132
SPI-183 - Drug Profile 133
SUD-004 - Drug Profile 134
Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction - Drug Profile 135
Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile 136
tacrolimus - Drug Profile 137
tadalafil - Drug Profile 138
tiprelestat - Drug Profile 140
tocilizumab - Drug Profile 143
TR-422 - Drug Profile 147
treprostinil - Drug Profile 148
treprostinil diolamine - Drug Profile 149
TXA-127 - Drug Profile 150
ubenimex - Drug Profile 153
udenafil - Drug Profile 154
Pulmonary Arterial Hypertension - Recent Pipeline Updates 156
Pulmonary Arterial Hypertension - Dormant Projects 185
Pulmonary Arterial Hypertension - Discontinued Products 188
Pulmonary Arterial Hypertension - Product Development Milestones 189
Featured News & Press Releases 189
Appendix 197
Methodology 197
Coverage 197
Secondary Research 197
Primary Research 197
Expert Panel Validation 197
Contact Us 197
Disclaimer 198List of Tables
Number of Products under Development for Pulmonary Arterial Hypertension, H1 2016 14
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 17
Number of Products under Development by Companies, H1 2016 (Contd..1) 18
Number of Products under Development by Companies, H1 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Comparative Analysis by Late Stage Development, H1 2016 21
Comparative Analysis by Clinical Stage Development, H1 2016 22
Comparative Analysis by Early Stage Development, H1 2016 23
Products under Development by Companies, H1 2016 24
Products under Development by Companies, H1 2016 (Contd..1) 25
Products under Development by Companies, H1 2016 (Contd..2) 26
Products under Development by Companies, H1 2016 (Contd..3) 27
Products under Investigation by Universities/Institutes, H1 2016 28
Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics, Inc., H1 2016 29
Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 30
Pulmonary Arterial Hypertension - Pipeline by Asahi Kasei Pharma Corp., H1 2016 31
Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H1 2016 32
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca, S.A., H1 2016 33
Pulmonary Arterial Hypertension - Pipeline by Bristol-Myers Squibb Company, H1 2016 34
Pulmonary Arterial Hypertension - Pipeline by Carolus Therapeutics, Inc., H1 2016 35
Pulmonary Arterial Hypertension - Pipeline by Celsion Corporation, H1 2016 36
Pulmonary Arterial Hypertension - Pipeline by Complexa, Inc., H1 2016 37
Pulmonary Arterial Hypertension - Pipeline by Corridor Pharmaceuticals Inc., H1 2016 38
Pulmonary Arterial Hypertension - Pipeline by Cytokinetics, Inc., H1 2016 39
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H1 2016 40
Pulmonary Arterial Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 41
Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences, Inc., H1 2016 42
Pulmonary Arterial Hypertension - Pipeline by Insmed Incorporated, H1 2016 43
Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 44
Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H1 2016 45
Pulmonary Arterial Hypertension - Pipeline by Kowa Company, Ltd., H1 2016 46
Pulmonary Arterial Hypertension - Pipeline by Mallinckrodt Plc, H1 2016 47
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H1 2016 48
Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics, Inc., H1 2016 49
Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Limited, H1 2016 50
Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co., Ltd., H1 2016 51
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 52
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H1 2016 53
Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics, Inc., H1 2016 54
Pulmonary Arterial Hypertension - Pipeline by PharmaIN Corporation, H1 2016 55
Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016 56
Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc., H1 2016 57
Pulmonary Arterial Hypertension - Pipeline by Proteo, Inc., H1 2016 58
Pulmonary Arterial Hypertension - Pipeline by Pulmokine, Inc., H1 2016 59
Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 60
Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics, Inc., H1 2016 61
Pulmonary Arterial Hypertension - Pipeline by Selten Pharma, Inc, H1 2016 62
Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H1 2016 63
Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H1 2016 64
Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H1 2016 65
Pulmonary Arterial Hypertension - Pipeline by Toray Industries, Inc., H1 2016 66
Assessment by Monotherapy Products, H1 2016 67
Number of Products by Stage and Target, H1 2016 69
Number of Products by Stage and Mechanism of Action, H1 2016 73
Number of Products by Stage and Route of Administration, H1 2016 76
Number of Products by Stage and Molecule Type, H1 2016 78
Pulmonary Arterial Hypertension Therapeutics - Recent Pipeline Updates, H1 2016 160
Pulmonary Arterial Hypertension - Dormant Projects, H1 2016 189
Pulmonary Arterial Hypertension - Dormant Projects (Contd..1), H1 2016 190
Pulmonary Arterial Hypertension - Dormant Projects (Contd..2), H1 2016 191
Pulmonary Arterial Hypertension - Discontinued Products, H1 2016 192List of Figures
Number of Products under Development for Pulmonary Arterial Hypertension, H1 2016 14
Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Investigation by Universities/Institutes, H1 2016 20
Comparative Analysis by Late Stage Development, H1 2016 21
Comparative Analysis by Clinical Stage Development, H1 2016 22
Comparative Analysis by Early Stage Products, H1 2016 23
Assessment by Monotherapy Products, H1 2016 67
Number of Products by Top 10 Targets, H1 2016 68
Number of Products by Stage and Top 10 Targets, H1 2016 68
Number of Products by Top 10 Mechanism of Actions, H1 2016 72
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 72
Number of Products by Routes of Administration, H1 2016 75
Number of Products by Stage and Routes of Administration, H1 2016 75
Number of Products by Top 10 Molecule Types, H1 2016 77
Number of Products by Stage and Top 10 Molecule Types, H1 2016 77
Market Intel Report Pulmonary Arterial Hypertension- Pipeline Review, H1 2015
By: Global Markets Direct | Published Date : 19 March, 2015 | No of Pages : 181
Market Intel Report Pulmonary Arterial Hypertension - Pipeline Review, H2 2015
By: Global Markets Direct | Published Date : 23 September, 2015 | No of Pages : 173
Market Intel Report Pulmonary Arterial Hypertension - Pipeline Review, H2 2016
By: Global Markets Direct | Published Date : 14 September, 2016 | No of Pages : 214
Market Intel Report Pulmonary Arterial Hypertension - Pipeline Review, H1 2017
By: Global Markets Direct | Published Date : 08 March, 2017 | No of Pages : 227
Market Intel Report Pulmonary Arterial Hypertension - Pipeline Review, H2 2017
By: Global Markets Direct | Published Date : 12 September, 2017 | No of Pages : 266
APT Therapeutics, Inc. Arena Pharmaceuticals, Inc. Asahi Kasei Pharma Corp. Ascendis Pharma A/S Bial - Portela & Ca, S.A. Bristol-Myers Squibb Company Carolus Therapeutics, Inc. Celsion Corporation Complexa, Inc. Corridor Pharmaceuticals Inc. Cytokinetics, Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. Insmed Incorporated INVENT Pharmaceuticals, Inc. Johnson & Johnson Kowa Company, Ltd. Mallinckrodt Plc Mezzion Pharma Co. Ltd. miRagen Therapeutics, Inc. Morphogen-IX Limited Nippon Kayaku Co., Ltd. Nippon Shinyaku Co., Ltd. Novartis AG Peloton Therapeutics, Inc. PharmaIN Corporation PhaseBio Pharmaceuticals, Inc. Pluristem Therapeutics Inc. Proteo, Inc. Pulmokine, Inc. Reata Pharmaceuticals, Inc. Respira Therapeutics, Inc. Selten Pharma, Inc Silence Therapeutics Plc SteadyMed Therapeutics, Inc. Suda Ltd Toray Industries, Inc.
Please select License
Single User Price:$ 2000
Site License Price:$ 4000
Enterprise Price:$ 6000